Boniva (ibandronate)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

View the Osteoporosis Slideshow Pictures

STORAGE: Ibandronate tablets should be stored at room temperature, 15 C - 30 C (59 F - 86 F).

DOSING:

  • The dose of ibandronate is 150 mg orally once monthly.
  • The tablet should be taken on the same day of each month.
  • Tablets should be taken at least 60 minutes before the first food or drink of the day (other than plain water) or before other oral medication, because of concern that that food or medication will interfere with the absorption of ibandronate. Absorption of ibandronate from the intestine is poor, and any potential further decrease in absorption by food or medications needs to be avoided.
  • Ibandronate tablets also should be swallowed whole with six to eight ounces of plain water while in an upright position, in order to be certain that the tablets enter the stomach. If the tablets stick in the esophagus they can irritate the esophagus. For the same reason, patients should not lie down for 60 minutes after taking ibandronate since tablets are more likely to stick in the esophagus when lying down.
  • Tablets should not be chewed or sucked in order to avoid irritation of the mouth and throat.
  • The dose of ibandronate administered intravenously is 3 mg administered over 15-30 seconds every three months.

DRUG CLASS AND MECHANISM:

  • Ibandronate is an oral and intravenous drug that is used for treating osteoporosis. It is a member of the bisphosphonate class of drugs which includes etidronate (Didronel), pamidronate (Aredia), risedronate (Actonel), and tiludronate (Skelid). Bone is in a constant state of remodeling. New bone is laid down by cells called osteoblasts while old bone is removed by cells called osteoclasts. Bisphosphonates strengthen bone by inhibiting bone removal (resorption) by osteoclasts. After menopause, there is an increased rate of bone loss leading to osteoporosis, and ibandronate has been shown to increase bone density and decrease fractures of bones.
  • FDA approved ibandronate in May 2003.

Reference: FDA Prescribing Information

Medically Reviewed by a Doctor on 8/5/2016

Quick GuideWhat Is Osteoporosis? Treatment, Symptoms, Medication in Pictures

What Is Osteoporosis? Treatment, Symptoms, Medication in Pictures
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: ibandronate on RxList
RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Women's Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors